Marked increases in funding: the NIH budget for research in 2011 was more than US$30 billion. Large amounts of money can distort priorities for research and shift the focus away from urgent publichealth needs on the basis of the belief that all research products merit clinical evaluation. The number of products in the therapeutic pipeline is rising and there is no informed method for prioritizing those which should move into clinical research. This increases the risk for people who participate in research.
Increased cost of clinical research and fewer treatment-naive individuals (those who have not been treated with any drugs of the class in question) in the United States: the number of research participants required to obtain statistically significant results for new products has increased drastically because of the need to compare these products with ones that are known to work. A 'mining' approach to obtaining treatment-naive people for research in poor countries has evolved, enlisting vulnerable populations. In some circumstances, the stated benefit for the individual may be limited to the future good of 'mankind' , a concept not easily understood in cultures in which health care is deficient. The shift to resource-poor countries is often accomplished by reducing standard of care, exaggerating potential benefits, the use of inferior treatment comparisons and the enrolment of vulnerable people not fully informed of their legal or ethical rights. Although the use of such practices has previously seen pharmaceutical companies criticized, they are increasingly used in academic circles to justify clinical trials funded by the federal government. A common defence is that breaches of ethical and scientific guidelines are rare. But the Presidential Commission's conclusion clearly states that there is a problem. And the World Medical Association has recently called for revisions of its ethical guidelines, emphasizing that concerns are widespread.
These issues must be resolved before the cracks become fissures. The HHS, the NIH and universities must acknowledge that the current research-approval process is flawed and requires an urgent, comprehensive review that should include experts and leaders from outside the academic community. This review must assess and make recommendations on how research priorities can be established, the means to select the most deserving products for clinical trials, how to expand IRB membership to include greater scientific and ethical expertise, how to minimize conflicts of interest and how to increase public input into decision-making for clinical research. ■
